Drug
Remdesivir clinical trials
Also written Veklury and GS-5734.
- studies test it
- 49
- open now
- 10
- in phase 3
- 26
- first study started
- 2016
Keep track of what changes. Save the remdesivir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
49 studies that test it; most in 2020 (27)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2018 | 1 |
| 2020 | 27 |
| 2021 | 10 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 3
- Phase 2
- 19
- Phase 3
- 26
- Phase 4
- 5
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 36
Who runs them
Industry 10 · Other 39
Gilead Sciences (6) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Capital Medical University (2) · QuantumLeap Healthcare Collaborative (1) · University of Melbourne (1) · Lisa Barrett (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · University of Derby (1)
Often tested with
Tested in the same studies.
Hydroxychloroquine (8) · Lopinavir-ritonavir drug combination (6) · Tocilizumab (5) · Interferon beta-1a (4) · Nirmatrelvir (3) · Ritonavir (3) · Nirmatrelvir and ritonavir drug combination (3) · Ivermectin (3)
Studies
Open first, then newest update. How each study uses remdesivir is read from its arms, and is right about nine times in ten.
Testing it · 49
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy TrialRecruitingPhase 2ANRS, Emerging Infectious DiseasesNCT05587894Written as Veklury
- A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely ImmunocompromisedRecruitingPhase 3PfizerNCT07013474Written as remdesivir
- Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised IndividualsRecruitingPhase 2Fred Hutchinson Cancer CenterNCT06817889Written as Remdesivir
- Adaptive Dengue Antiviral Platform TrialRecruitingPhase 2Oxford University Clinical Research Unit, VietnamNCT06551844Written as Remdesivir 100mg
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)RecruitingPhase 2University of OxfordNCT05041907Written as Remdesivir
- Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant PatientsRecruitingPhase 2Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaNCT07197164Written as Remdesivir (RDV)
- Safety, Pharmacokinetics, and Antiviral Activity of Remdesivir (VEKLURY®) in Hospitalized Children With RSVRecruitingPhase 2PENTA FoundationNCT06873633Written as Remdesivir
- Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical TrialRecruitingPhase 4Mount Sinai Hospital, CanadaNCT06792214Written as Remdesivir
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingPhase 3UMC UtrechtNCT02735707Written as Remdesivir
- LUSZ Treatment Efficacy in Hospitalized COVID-19 PatientsRecruitingPhase 1Lebanese UniversityNCT05925140Written as Remdesivir (RDV)
- Trial of Treatments for COVID-19 in Hospitalized AdultsCompletedPhase 3Institut National de la Santé Et de la Recherche Médicale, FranceNCT04315948Written as Remdesivir
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsActive, not recruitingPhase 2QuantumLeap Healthcare CollaborativeNCT04488081Written as Remdesivir
- An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.CompletedPhase 4University of DerbyNCT05911906Written as Remdesivir
- ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04843761Written as Remdesivir
- Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT06729593Written as Remdesivir
- An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANYWithdrawnPhase 2/3Professor Dr. Bernd MühlbauerNCT04575064Written as Remdesivir
- Australasian COVID-19 Trial (ASCOT) ADAptive Platform TrialActive, not recruitingPhase 3University of MelbourneNCT04483960Written as Remdesivir
- Study of Remdesivir in Participants Below 18 Years Old With COVID-19CompletedPhase 2/3Gilead SciencesNCT04431453Written as Remdesivir
- Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 PatientsTerminatedPhase 3Daewoong Pharmaceutical Co. LTD.NCT04713176Written as DWJ1248 with Remdesivir
- Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized PatientsActive, not recruitingPhase 2Lisa BarrettNCT04321993Written as Remdesivir (antiviral)
See all 49 studies that test remdesivir →
Given in every arm · 21 — remdesivir is usual care beside what is tested
- SARS-CoV-2 Human Challenge Characterisation StudyCompletedNot applicableImperial College LondonNCT04865237Written as Remdesivir
- AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780437Written as Remdesivir
- Baricitinib in Hospitalized Covid-19 Patients With Diabetes MellitusWithdrawnPhase 3Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic DisordersNCT04970719Written as Remdesivir
- PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)TerminatedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780541Written as Remdesivir
- BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780424Written as Remdesivir
- MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780463Written as Remdesivir
- LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780268Written as Remdesivir
- VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780281Written as Remdesivir
- Immune Modulators for Treating COVID-19CompletedPhase 3Daniel BenjaminNCT04593940Written as Remdesivir
- ACTIV-3: Therapeutics for Inpatients With COVID-19CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04501978Written as Remdesivir
- COVID-19 and Anti-CD14 Treatment TrialTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04391309Written as remdesivir
- ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19CompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04988035Written as Remdesivir
- ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19CompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04583969Written as Remdesivir
- ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19CompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04583956Written as Remdesivir
- Adaptive COVID-19 Treatment Trial 4 (ACTT-4)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04640168Written as Remdesivir
- Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)CompletedPhase 3University of MinnesotaNCT04546581Written as Remdesivir
- Adaptive COVID-19 Treatment Trial 3 (ACTT-3)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04492475Written as Remdesivir
- Adaptive COVID-19 Treatment Trial 2 (ACTT-2)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04401579Written as Remdesivir
- A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 PneumoniaCompletedPhase 3Hoffmann-La RocheNCT04409262Written as Remdesivir
- Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 PatientsStatus unknownPhase 3M Abdur Rahim Medical College and HospitalNCT04693026Written as Remdesivir
Showing 20 of 21.
As the comparator · 4 — what is tested is compared with remdesivir
- A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult SubjectsCompletedPhase 1Heronova PharmaceuticalsNCT06860282Written as Remdesivir
- Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 InfectionTerminatedPhase 3PharmaMarNCT04784559Written as Remdesivir
- Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19CompletedPhase 3Promomed, LLCNCT05185284Written as Remdesivir
- IFN-beta 1b and Remdesivir for COVID19Status unknownPhase 2The University of Hong KongNCT04647695Written as Remdesivir
Codes
What other systems call remdesivir · ClinicalTrials.gg INT000432
- MeSH (NLM) C000606551remdesivirConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3QKI37EEHEREMDESIVIRConfirmed FDA, NLM, Wikidata
- RxNorm 2284718Confirmed FDA, Wikidata
- Wikidata Q28209496remdesivirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152185RemdesivirOne source FDA
- DrugBank DB14761One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000606551 | remdesivir | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3QKI37EEHE | REMDESIVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2284718 | — | Confirmed FDA, Wikidata |
| Wikidata | Q28209496 | remdesivir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152185 | Remdesivir | One source FDA |
| DrugBank | DB14761 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.